The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0706 ET – AstraZeneca should continue to deliver growth and innovation ahead of peers over the medium term, UBS analysts write. The British drugmaker’s recent U.S. drug pricing deal might lead to a slight, still-uncertain drag on 2026 profitability, but the group is unlikely to change its goal of hitting a core operating margin in the mid-30s range, the analysts say. The company omitted the goal from its presentation, which has triggered debate, they add. Inventory reductions and hospital budget caps in China might weigh on fourth-quarter earnings, but the company’s guidance still leaves room for AstraZeneca to beat full-year consensus expectations, according to UBS. Shares fall 0.1%. (william.gray@wsj.com)

Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8